富血小板血对支气管的有效性和安全性:试点前性队列研究
Yongshun Ye1, Tingting Xu2, Jinxia Lin2
1Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Huizhou Central People's Hospital, Huizhou, China.
Archivos de bronconeumologia
|August 30, 2024
概括
富含血小板血 (PRP) 有效地治疗手术后的小支气管肺 (BPF). 这种微侵袭性疗法显示出高的成功率,并改善呼吸道症状,副作用最小.
科学领域:
- 再生医学是一种再生医学.
- 肺部医学 肺部医学
- 手术创新 在外科创新.
背景情况:
- 支气管口腔 (BPF) 在肺切除后提出了重大挑战,对于小的选择有限.
- 现有的手术,支气管镜检查和保守治疗等治疗方法具有固有的局限性.
- 富血小板血 (PRP) 为组织修复提供了再生潜力,使其成为BPF治疗的候选者.
研究的目的:
- 评估丰富血小板血 (PRP) 的疗效和安全性,用于治疗小支气管肺 (BPF).
- 评估PRP在BPF关闭中的治愈率,改善率和无效性.
- 调查PRP对呼吸系统症状严重程度和患者安全的影响.
主要方法:
- 一项试点前性队列研究,涉及16名BPF小于4mm的患者.
- PRP是通过支气管镜进行的,治疗后2周和4-6周进行了随访.
- 测量结果包括关闭率,呼吸道症状得分 (mMRC,CAT) 和不良事件.
主要成果:
- 通过PRP治疗,囊在12.0天的中位数内关闭.
- 观察到的整体有效率为87.6% (68.8%的治愈,18.8%的改善).
- 在mMRC和CAT得分中发现了显著的改善 (P<0.001),没有瘤复发,感染或死亡. 轻度,暂时的不良事件发生在82.6%的患者中.
结论:
- 富血小板血 (PRP) 显示出作为小支气管管的安全和有效治疗的巨大潜力.
- PRP疗法耐受性良好,并导致BPF患者的临床状况明显改善.
- 这项研究支持PRP作为一种有希望的再生方法,用于管理BPF肺切除后的肺切除.
相关概念视频
01:26Flail Chest-II
160
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
160
01:27Pneumothorax-II
127
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
127
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
160
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
160